Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:38 AM
Ignite Modification Date:
2025-12-25 @ 12:38 AM
NCT ID:
NCT05169567
Eligibility Criteria:
Inclusion Criteria:
* Have a diagnosis of HR+, HER2- locally advanced or metastatic breast cancer
* Have radiologic evidence of disease progression or recurrence either
* On treatment with a CDK4/6 inhibitor with aromatase inhibitor (AI) as initial therapy for advanced disease, or
* On/after treatment with a CDK4/6 inhibitor plus endocrine therapy (ET) administered as adjuvant therapy for early stage breast cancer
* Must be deemed appropriate for treatment with ET
* If female, have a postmenopausal status by natural or surgical means or by ovarian function suppression
* Have Response Evaluable Criteria in Solid Tumors (RECIST) evaluable disease (measurable disease and/or nonmeasurable disease)
* Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group scale (Oken et al. 1982)
* Have adequate renal, hematologic, and hepatic organ function
* Must be able to swallow capsules/tablets
Exclusion Criteria:
* Have visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis
* Have symptomatic or untreated central nervous system metastasis
* Have received any systemic therapy between disease recurrence/progression and study screening
* Have received more than 1 line of therapy for advanced or metastatic disease.
* Have received prior chemotherapy for metastatic breast cancer (MBC)
* Have received prior treatment with fulvestrant, any investigational estrogen receptor (ER)-directed therapy (including selective ER degraders \[SERDs\] and non-SERDs), any phosphatidylinositol 3-kinase (PI3K)-, mammalian target of rapamycin (mTOR)-, or protein kinase B (AKT)-inhibitor
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT05169567
Study Brief:
Protocol Section:
NCT05169567